Fangzhou Inc. <\/p>\n
SHANGHAI, Nov. 07, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (\u201cFangzhou\u201d or the \u201cCompany\u201d) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, was invited to the \u201cBoundless Care, New Beginnings\u201d 2025 Health Ecosystem Partner Alliance Summit and New Product Launch Ceremony, hosted by Novo Nordisk at the 8th China International Import Expo (\u201cCIIE\u201d) in Shanghai.<\/p>\n
Novo Nordisk announced the expansion of its Health Ecosystem Alliance, first introduced in 2023. Fangzhou was named an \u201cOutstanding Strategic Health Ecosystem Partner,\u201d recognizing its role in advancing digital innovation in chronic disease management.<\/p>\n
Fangzhou was named an \u201cOutstanding Strategic Health Ecosystem Partner\u201d <\/p>\n
Fangzhou was named an \u201cOutstanding Strategic Health Ecosystem Partner\u201d<\/p>\n
The \u201cHealth Ecosystem Alliance\u201d serves as a collaborative platform that facilitates joint development and synergies among ecosystem partners. As a core member, Fangzhou shares a common vision with Novo Nordisk in advancing digital innovation for chronic disease management. In July 2025, the two companies signed a strategic partnership to better align service offerings and patient needs, jointly developing digital chronic disease management models that empower healthcare stakeholders while benefiting patients. Moving forward, Fangzhou will work closely with Novo Nordisk to develop a digital chronic disease management ecosystem, fostering continued innovation and development in the healthcare sector.<\/p>\n
Fangzhou has established itself as a leader in integrating AI technology into weight management, creating the industry\u2019s first intelligent \u201cAI + Weight Management\u201d solution. The company was also selected as a key participant in the national \u201cHealthy China: AI + Weight Management Initiative,\u201d in collaboration with the China Food and Drug Institutions Quality and Safety Promotion Association, promoting standardization, technological advancement, and evidence-based approaches.<\/p>\n
At the same time, Fangzhou has also strengthened its presence in AI-powered diabetes management, receiving strong recognition from Novo Nordisk for its capabilities in AI-driven healthcare services and medication management. Leveraging Fangzhou\u2019s digital infrastructure and Novo Nordisk\u2019s innovative therapies for diabetes and obesity, the two companies are jointly advancing a shift from \u201cdisease-focused treatment\u201d to \u201cproactive health management.\u201d Novo Nordisk described the collaboration as a milestone in integrating chronic disease prevention with digital innovation, forging a new direction for intelligent healthcare transformation.<\/p>\n
Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, remarked: \u201cAs a key partner of Novo Nordisk\u2019s Health Ecosystem Alliance, Fangzhou will continue to leverage our XJ and XS Large Language Models as the cornerstone of our AI infrastructure, deepening technological innovation to deliver accessible, efficient, end-to-end chronic disease management services to a broader population.\u201d<\/p>\n
Throughout 2025, Fangzhou has continued to expand and enhance its AI + Chronic Disease Management ecosystem, driving the industry\u2019s transition from traditional care models to systematized, evidence-based models. Through an open and collaborative approach, the Company plans to work with industry leaders to improve the quality and efficiency of digital healthcare \u2014 contributing powerful momentum to the Healthy China 2030 goals.<\/p>\n
About Novo Nordisk<\/strong> About Fangzhou Inc.<\/strong> Media Contact<\/strong> Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements<\/p>\n A photo accompanying this announcement is available at:<\/p>\n
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Novo Nordisk\u2019s purpose is to drive change to defeat serious chronic diseases built upon its heritage in diabetes. The company does so by pioneering scientific breakthroughs, expanding access to its medicines and working to prevent and ultimately cure disease.<\/p>\n
Fangzhou Inc. (HKEX: 06086) is China\u2019s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, visit https:\/\/investors.jianke.com<\/a>.<\/p>\n
For further inquiries or interviews, please reach out to:
Xingwei Zhao<\/strong>\u00a0Associate Director of Public Relations Email: pr@jianke.com<\/p>\n